Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Tanomastat is an inhibitor of matrix metalloproteinase-2 (MMP-2), MMP-3, and MMP-9 (Kis = 11, 143, and 301 nM, respectively).1 It is selective for MMP-2, -3, and -9 over MMP-1 and MMP-13 (Kis = 5,000 and 1,470 nM, respectively). Tanomastat (15 µM) inhibits VEGF- and FGF-induced tubule formation in human umbilical vein endothelial cells (HUVECs).2 It reduces tumor growth and the number of pulmonary metastases in an MDA-MB-435 orthotopic mouse model of breast cancer when administered at a dose of 100 mg/kg. Tanomastat (50 mg/kg) decreases disease severity in a rat model of adjuvant-induced arthritis.3
WARNING This product is not for human or veterinary use.
1. Protease inhibitors: Current status and future prospects. J. Med. Chem. 43(3), 305-341 (2000).
2. Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-
3. Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase-